Author:
Schultz Neil M.,Flanders Scott C.,Wilson Samuel,Brown Bruce A.,Song Yan,Yang Hongbo,Lechpammer Stanislav,Kassabian Vahan
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference32 articles.
1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase no. 11. 2014.
http://globocan.iarc.fr
. Accessed 22 Mar 2018.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
3. Sonpavde G, Pond GR, Armstrong AJ, et al. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU Int. 2014;114(6b):E25–31.
4. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–92.
5. National Cancer Institute. Prostate cancer treatment-health professional version (PDQ®). 2018.
http://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq
. Accessed 7 Jul 2018.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献